OBJECTIVE: To investigate the clinical features and prognostic factors of patients with primary extranodal diffuse large B-cell lymphoma (DLBCL) in the rituximab era.
METHODS: The continuous data of newly diagnosed DLBCL patients with complete case data and first-line treated with rituximab, cyclophosphamide, epirubicin,
vincristine, prednisone (R-CHOP) or R-CHOP treatment admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2013 to November 2023 were retrospectively analyzed. The clinical and molecular immunological features and prognosis of extranodal DLBCL were analyzed, Logistics regression model was used to analyzed the influencing factors of patients prognosis.
RESULTS: A total of 237 patients were enrolled, of which 54.4% (129 cases) were primary extranodal sources of DLBCL, and the most common extranodal sites were as follows: stomach (19.4%), colon (14.7%), tonsils (12.4%), skin/muscle (9.3%), central (7.7%), nasal/nasopharynx (6.2%), bone marrow (5.4%), testes (4.7%). The 3-year PFS and OS of DLBCL patients with extranodal involvement of bone marrow, central, liver, gastrointestinal or pulmonary origin were significantly lower than those of other patients with extranodal DLBCL of non-special site origin, and the difference was statistically significant (PFS: 65.2% vs 76.7%, P =0.008; OS: 82.6% vs 88.3%, P =0.04). Multivariate analysis showed that the prognostic factors affecting OS included NCCN-IPI score >3 (OR : 0.142, 95%CI : 0.041-0.495, P =0.002), non-germinal center source (OR : 2.675,95%CI :1.069-6.694,P =0.036), and DEL patients (OR : 0.327, 95%CI : 0.129-0.830, P =0.019). An NCCN-IPI score >3 was the only independent adverse prognostic factor for PFS (OR : 0.235, 95%CI : 0.116-0.474, P < 0.001).
CONCLUSIONS: Patients with primary extranodal source DLBCL are more common in gastrointestinal involvement, and the overall prognosis is worse than that of patients with lymph node origin. NCCN-IPI score is an important independent adverse prognostic factor for predicting overall survival and progression-free survival in patients with primary extranodal diffuse large B-cell lymphoma.
UNASSIGNED: 利妥昔单抗时代原发结外弥漫性大B细胞淋巴瘤:单中心回顾分析.
UNASSIGNED: 探讨利妥昔单抗治疗时代下原发结外弥漫性大B细胞淋巴瘤(DLBCL)患者的临床特征及预后影响因素。.
UNASSIGNED: 回顾性分析2013年1月至2023年11月内蒙古医科大学附属医院收治的一线予以利妥昔单抗、环磷酰胺、表柔比星、长春新碱、泼尼松 (R-CHOP) 或 R-CHOP 类方案化疗且具有完整病例资料的初诊DLBCL患者的连续数据,分析结外DLBCL患者的临床特征、分子免疫学特征及预后,应用Logistics回归模型分析患者预后的影响因素。.
UNASSIGNED: 共纳入237例患者,其中54.4%(129例)为原发结外来源DLBCL,常见的结外部位分别为胃(19.4%)、结肠(14.7%)、扁桃体(12.4%)、皮肤或肌肉(9.3%)、中枢(7.7%),鼻或鼻咽(6.2%)、骨髓(5.4%)、睾丸(4.7%)。其中,骨髓、中枢、肝脏、胃肠道或肺部起源的结外DLBCL患者3年PFS及OS均明显低于其余非特殊部位结外DLBCL患者,差异具有统计学意义(PFS,65.2% vs 76.7% P =0.008;OS:82.6% vs 88.3%,P =0.04)。多因素分析结果显示,影响结外DLBCL患者OS的预后因素包括:NCCN-IPI评分>3分(OR :0.142,95%CI :0.041-0.495,P =0.002),非生发中心来源(OR :2.675,95%CI :1.069-6.694,P =0.036)和双表达(DEL)患者(OR :0.327,95%CI :0.129-0.830,P =0.019)。NCCN-IPI评分>3分是影响PFS的唯一独立不良预后因素(OR :0.235,95%CI :0.116-0.474,P < 0.001)。.
UNASSIGNED: 本中心原发结外DLBCL患者最多见于胃肠道受累,所有结外DBLCL患者中骨髓、中枢、肝脏、胃肠道或肺部起源的患者预后更差。NCCN-IPI评分是预测原发结外DLBCL患者总生存和无进展生存的独立不良预后因素。.